aTyr Pharma (LIFE) versus Nektar Therapeutics (NKTR) Head-To-Head Review

aTyr Pharma (NASDAQ: LIFE) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Insider and Institutional Ownership

58.3% of aTyr Pharma shares are owned by institutional investors. Comparatively, 96.0% of Nektar Therapeutics shares are owned by institutional investors. 33.3% of aTyr Pharma shares are owned by company insiders. Comparatively, 6.1% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares aTyr Pharma and Nektar Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
aTyr Pharma N/A -87.33% -65.25%
Nektar Therapeutics -42.08% -190.68% -19.50%

Earnings & Valuation

This table compares aTyr Pharma and Nektar Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
aTyr Pharma N/A N/A -$57.85 million ($2.03) -1.90
Nektar Therapeutics $165.44 million 54.98 -$153.52 million ($0.71) -81.35

aTyr Pharma has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for aTyr Pharma and Nektar Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma 0 3 1 0 2.25
Nektar Therapeutics 0 1 12 0 2.92

aTyr Pharma currently has a consensus price target of $5.00, indicating a potential upside of 29.87%. Nektar Therapeutics has a consensus price target of $36.64, indicating a potential downside of 36.57%. Given aTyr Pharma’s higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Nektar Therapeutics.

Risk and Volatility

aTyr Pharma has a beta of 3.83, meaning that its stock price is 283% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.

Summary

aTyr Pharma beats Nektar Therapeutics on 7 of the 13 factors compared between the two stocks.

About aTyr Pharma

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply